Fludarabine

Research use only, not for human use.

Fludarabine(NSC 118218), a DNA synthesis inhibitor.

Fludarabine(NSC 118218), a DNA synthesis inhibitor, is a chemotherapy drug used in the treatment of hematological malignancies.(In Vitro):Fludarabine (5 μM; 48?hours) induces a decrease in p27kip1 expression.(In Vivo):Fludarabine (0.8?mg/kg; i.p.; two cycles for 5 days every 2 weeks) in combination with Cyclophosphamide (400?mg/kg; i.p.; 2 weeks) decreases incidence of GVHD.

Fludarabine (5 μM; 48?hours) induces a decrease in p27kip1 expression.Western Blot Analysis Cell Line:B-CLL cells Concentration:5 μM Incubation Time:24 hours Result:Induces a decrease in p27kip1 expression. The decrease in p27kip1 expression was significantly correlated to the extent of in vitro apoptosis.

Fludarabine (0.8?mg/kg; i.p.; two cycles for 5 days every 2 weeks) in combination with Cyclophosphamide (400?mg/kg; i.p.; 2 weeks) decreases incidence of GVHD. Animal Model:F-1 mice received 105 BCL-1 leukemia cells Dosage:0.8?mg/kg Administration:Intraperitoneal injection; two cycles for 5 days every 2 weeks Result:Combination with Cyclophosphamide decreased incidence of graft-versus-host disease (GVHD).

F-ara-A | NSC 118218

JAK/STAT Signaling

STAT

STAT1

Cancer

——

21679-14-1

285.23

C10H12FN5O4

>98% (HPLC)

DMSO: 57 mg/mL (199.83 mM)

NC1=C2N=CN([C@H]3[C@H]([C@@H]([C@@H](CO)O3)O)O)C2=NC(F)=N1

(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

(-20℃)

With Ice Pack

≥ 2 years